DDInter622 DDInter1376
A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Edrophonium {u} (Compound) resembles {v} (Compound) Metaraminol
Edrophonium {u} (Compound) resembles {v} (Compound) Tapentadol
Edrophonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neostigmine
Edrophonium {u} (Compound) binds {v} (Gene) BCHE
Edrophonium {u} (Compound) upregulates {v} (Gene) IL1R2
Edrophonium {u} (Compound) downregulates {v} (Gene) MAP7
Edrophonium {u} (Compound) causes {v} (Side Effect) Conjunctival hyperaemia
Edrophonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pyridostigmine
Edrophonium (Compound) resembles Metaraminol (Compound)
Edrophonium (Compound) resembles Tapentadol (Compound)
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Edrophonium (Compound) binds BCHE (Gene)
Edrophonium (Compound) upregulates IL1R2 (Gene)
Edrophonium (Compound) downregulates MAP7 (Gene)
Edrophonium (Compound) causes Conjunctival hyperaemia (Side Effect)
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine